

Dr. Wisoot Wongklahan Thai Phlebology Society

https://www.facebook.com/เส้นเลือดขอดรักษาได้ไม่

<u>ต้องผ่าตัด</u>

Line ID: drwis



General health condition

- 1. Carefully taken medical history
- 2. Procedure is elective so patients should be healthy (ASA I,II)
- 3. Patients on long-term oral anticoagulation safely treat with ETA
- 4. Previous operation
- 5. Obesity

Original Article

Guidelines of the First International Consensus Conference on Endovenous Thermal Ablation for Varicose Vein Disease – ETAV Consensus Meeting 2012

Miloš D Pavlović¹, Sanja Schuller-Petrović², Olivier Pichot³, Eberhard Rabe⁴, Uldis Maurins⁵, Nick Morrison⁶ and Felizitas Pannier⁷

Phlebology

Phlebology
2015, Vol. 30(4) 257–273
© The Author(s) 2014
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0268355514524568
phl.sagepub.com







Contraindications

Absolute contraindications

- Acute deep vein thrombosis (DVT),
- Acute superficial phlebitis,
- Acute infections at puncture sites (infection should be treated first),
- Deep venous obstruction if the vein to be treated is a functional collateral.

Relative contraindications

- Immobile or hardly ambulating patients
- Concomitant significant peripheral arterial disease with (ankle:brachial pressure index < 0.5 or an absolute ankle pressure < 60 mmHg)
- Patients unable to undergo local anesthesia
- Elevated thromboembolic risk including documented thrombophilia and history of previous DVT.
- Pregnancy
- Patients with significant uncompensated leg edema
- Uncontrolled severe diseases.





Technical issues which may be viewed as relative contraindications (GRADE IC)⁶⁵

- Tortuous vein difficult to catheterize
- Diameter of the vein at the accessing segment < 3 mm (may be difficult to puncture and pass the catheter)
- Partly occluded venous segment (intraluminal webs, thrombosed or hypoplastic)
- Vein segment to be treated shorter than necessary for catheter placement.

Treatment Plan



Discussed with the patient about findings

- Treatment option: ½ legs, stage treatment
- Patient expectation: Recurrent, Bulging, Ulcer, Leg swelling, Hyperpigmentation, Pain
- Cost
- Risk, Side effect
- Informed consent
- Instruction for Pre-op & Post-op care/time



In case Varicose vein closed to skin

- Recommendation : advise patient about Hard lump, Tenderness or cord like Presentation
- Switch to stripping or phlebectomy
- Invaginated Stripping
- Bulging Varicose Veins





Equivocal Problem

- Double Saphenous
- Accessory Saphenous Vein
- Both legs VS one leg
- GSV,SSV Segmental Reflux
- □ Puncture Point → Above knee, below knee, ankle
- Small Saphenous vein VS Sural Nerve
- Superficial Vein and Deep Vein Reflux



Operative Treatment


- Pre-medication- at home, at site Tranquilizer
- Pre-op Antibiotics
- Anticoagulant- No guideline may be use Caprini
 Thrombosis risk assessment
- Mapping- again- change



Canulation Trouble

- Vasospasm (Cold environment, Anxiety)
- Exercise 10-15 minute walk,
- Position Reverse Trendelenberg Position
- Tourniquet
- Keep warm air condition: turn off, increase temperature
 - Warm blanket
 - Warming pad
 - NTG pad





05/12/2019 12:54:50 PM





Solution

- Small Diameter : micropuncture set
- Failed:move up/move down
- Reverse puncture from SFJ, SPJ
 - Sapheno femoral Junction (SFJ)
 - Sapheno popliteal junction (SPJ)
- Venous cutdown
- Tortuous Vein Multiple Puncture/Double Prepuncture
 - Hand Manipulatioin, Mobilize leg
 - Flushing
- Narrowing Smaller guidewire








- Endovenous thermal ablation on Saphenous vien Relied on results and data interpretations of Klein's work on Tumescent anesthesia for liposuction.
- ☐ Perivenous space in saphenous sheath different from subcutaneous fat.



Safety Dose



1 gm lidocaine in 1110 ml 0.09%, 0.9 gm/Litr





Lidocaine with adrenaline safety dose

FDA Recommend 7 mg/kg

1989 Klein Recommend 35 mg/kg (with liposuction)

May 2016 Klein Recommend 45 mg/kg (with liposuction)

Recommend 28 mg/kg (without liposuction)

Estimated Maximal Safe Dosages of Tumescent Lidocaine

Jeffrey A. Klein, MD, MPH, *† and Daniel R. Jeske, PhD†

BACKGROUND: Tumescent lidocaine anesthesia consists of subcutaneous injection of relatively large volumes (up to 4 L or more) of dilute lidocaine (≤ 1 g/L), and epinephrine (≤ 1 mg/L). Although tumescent lidocaine anesthesia is used for an increasing variety of surgical procedures, the maximum safe dosage is unknown. Our primary aim in this study was to measure serum lidocaine concentrations after subcutaneous administration of tumescent lidocaine with and without liposuction. Our hypotheses were that even with large doses (i.e., >30 mg/kg), serum lidocaine concentrations would be below levels associated with mild toxicity and that the concentration-time profile would be lower after liposuction than without liposuction.

METHODS: Volunteers participated in 1 to 2 infiltration studies without liposuction and then one study with tumescent liposuction totally by local anesthesia. Serum lidocaine concentrations were measured at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 24 hours after each tumescent lidocaine infiltration. Area under the curve (AUC^{∞}) of the serum lidocaine concentration-time profiles and peak serum lidocaine concentrations (Cmax) were determined with and without liposuction. For any given milligram per kilogram dosage, the probability that Cmax >6 μ g/mL, the threshold for mild lidocaine toxicity was estimated using tolerance interval analysis.

RESULTS: In 41 turnescent infiltration procedures among 14 volunteer subjects, turnescent lidocaine dosages ranged from 19.2 to 52 mg/kg. Measured serum lidocaine concentrations were all <6 μ g/mL over the 24-hour study period. AUC ∞ s with liposuction were significantly less than those without liposuction (P = 0.001). The estimated risk of lidocaine toxicity without liposuction at a dose of 28 mg/kg and with liposuction at a dose of 45 mg/kg was \le 1 per 2000.

CONCLUSIONS: Preliminary estimates for maximum safe dosages of tumescent lidocaine are 28 mg/kg without liposuction and 45 mg/kg with liposuction. As a result of delayed systemic absorption, these dosages yield serum lidocaine concentrations below levels associated with mild toxicity and are a nonsignificant risk of harm to patients. (Anesth Analg 2016;122:1350–9)





Lidocaine safety after saphenous vein tumescent anesthesia 2019

- 35mg/kg: some toxicity/peak 60 mins
- 15 mg/kg: no toxicity/(180 mins)

Driginal Article


Lidocaine safety after saphenous vein tumescent anesthesia


Phlebology
2019, Vol. 34(10) 683–689
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0268355519836834
journals.sagepub.com/home/phl

SAGE

Thomas F Wright 1 , Giulietta F Brunetti 2 and
Patrick Kennedy 3









Tumescent Anesthesia Solution

0.09% or 0.1% lidocaine (Klein Formula)

- Use 5-10 ml/cm (vein length)
- 1 GSV (thigh) 40 cm = 200 400 ml.
- BW 60 kg = 15 mg/kg = 900 mg/900ml.
- Safety dose 1 gm/day

Conclusion

15 mg/kg is safe for normal young healthy patient In older patient, an ASA class III , need to be careful on lesser dose



Symptoms of local anesthetic toxicity

Early neurological symptoms

Circumoral and/or tongue numbness

Metallic taste

Lightheadedness

Dizziness

Visual and auditory disturbances (difficulty focusing and tinnitus)

Disorientation

Drowsiness

Severe respiratory and cardiovascular symptoms

Hypotension

Arrhythmia

Bradycardia

Cardiac arrest

Respiratory arrest

Risk factors

Pre-existing pulmonary, cardiac, and nervous vulnerabilities.

Large dose injection

Injection around vessel-rich region

Needle or catheter placement without imaging devices

Bolus injection without aspiration test

Injection without test dosing



Recognition of the symptoms of lidocaine toxicity

- Lack of awareness that the toxicity can occur during the vascular procedures using tumescent anesthesia.
- Lack of awareness of the symptoms of lidocaine toxicity.
- Overlap of symptoms with procedural anxiety.
- Misattribution of lidocaine to the side effects of epinephrine administration.
- Time delay from the administration of the lidocaine to the onset of symptoms.
- Lidocaine eliminate through hepatic metabolism/Enzyme CYP3A4

Treatment Record



- Technique ,Treatment time
- Power setting
- Vein Treated:location Length,Diameter
- Type of anesthesia
- Additional Procedure:Foam sclerotherapy ,Phlebectomy
- Compression
- Follow up visit

Post treatment advice



- Possible adverse event explain to Patient painful or swollen limbs
 - Chest pain ,cough or shortness of breath
 - Redness, heat or localized swelling
- Driving Immediately after treatment:not allowed
- No routine Prophylactic anticoagulant





ขอบคุณครบ

THANK YOU!



